Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls
Authors:
- 1 December 2014
- journal article
- review article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 101, 66-83
Abstract
No abstract availableKeywords
This publication has 148 references indexed in Scilit:
- Intolerability of cobalt salt as erythropoietic agentDrug Testing and Analysis, 2013
- Fortifying the Link between SIRT1, Resveratrol, and Mitochondrial FunctionCell Metabolism, 2012
- Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP PhosphodiesterasesCell, 2012
- Ryanodine Receptor Oxidation Causes Intracellular Calcium Leak and Muscle Weakness in AgingCell Metabolism, 2011
- Confiscated black market products and nutritional supplements with non‐approved ingredients analyzed in the cologne doping control laboratory 2009Drug Testing and Analysis, 2010
- The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary diseasePulmonary Pharmacology & Therapeutics, 2010
- Structural basis for sirtuin function: What we know and what we don'tBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- Comprehensive plasma‐screening for known and unknown substances in doping controlsRapid Communications in Mass Spectrometry, 2010
- Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscleNature Medicine, 2009
- AMPK and PPARδ Agonists Are Exercise MimeticsCell, 2008